AU2008305303A1 - Methods and compounds for treating retinol-related diseases - Google Patents

Info

Publication number

AU2008305303A1

AU2008305303A1 AU2008305303A AU2008305303A AU2008305303A1 AU 2008305303 A1 AU2008305303 A1 AU 2008305303A1 AU 2008305303 A AU2008305303 A AU 2008305303A AU 2008305303 A AU2008305303 A AU 2008305303A AU 2008305303 A1 AU2008305303 A1 AU 2008305303A1

Authority

AU

Australia

Prior art keywords

alkyl

formula

compound

optionally substituted

butyl

Prior art date

2007-09-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims description 357
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 title claims description 297
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 title claims description 165
• 239000011607 retinol Substances 0.000 title claims description 144
• 229960003471 retinol Drugs 0.000 title claims description 144
• 238000000034 method Methods 0.000 title claims description 130
• 235000020944 retinol Nutrition 0.000 title claims description 130
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 62
• 201000010099 disease Diseases 0.000 title claims description 54
• -1 methylenecyclopropyl Chemical group 0.000 claims description 164
• 108091000053 retinol binding Proteins 0.000 claims description 118
• 102000029752 retinol binding Human genes 0.000 claims description 118
• 125000000217 alkyl group Chemical group 0.000 claims description 115
• 241000124008 Mammalia Species 0.000 claims description 111
• 239000000203 mixture Substances 0.000 claims description 109
• 239000008194 pharmaceutical composition Substances 0.000 claims description 104
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 91
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 90
• 102000009190 Transthyretin Human genes 0.000 claims description 79
• 108010071690 Prealbumin Proteins 0.000 claims description 78
• 150000003839 salts Chemical class 0.000 claims description 77
• 208000002780 macular degeneration Diseases 0.000 claims description 70
• 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 68
• 239000000651 prodrug Substances 0.000 claims description 68
• 229940002612 prodrug Drugs 0.000 claims description 68
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 65
• 239000002207 metabolite Substances 0.000 claims description 65
• 210000002966 serum Anatomy 0.000 claims description 65
• 125000003342 alkenyl group Chemical group 0.000 claims description 63
• 125000001072 heteroaryl group Chemical group 0.000 claims description 63
• 239000012453 solvate Substances 0.000 claims description 61
• 125000003107 substituted aryl group Chemical group 0.000 claims description 59
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 57
• 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 57
• UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims description 54
• 230000000694 effects Effects 0.000 claims description 51
• 102100038246 Retinol-binding protein 4 Human genes 0.000 claims description 46
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 46
• 125000005843 halogen group Chemical group 0.000 claims description 43
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 39
• 229910052736 halogen Inorganic materials 0.000 claims description 39
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 39
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 38
• 230000027455 binding Effects 0.000 claims description 36
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 35
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 33
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 32
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 32
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 23
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 21
• 108090000623 proteins and genes Proteins 0.000 claims description 21
• 230000007850 degeneration Effects 0.000 claims description 20
• 238000011282 treatment Methods 0.000 claims description 20
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 19
• 102000004169 proteins and genes Human genes 0.000 claims description 19
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 17
• 208000008069 Geographic Atrophy Diseases 0.000 claims description 17
• 125000003118 aryl group Chemical group 0.000 claims description 17
• 239000003937 drug carrier Substances 0.000 claims description 17
• 206010012601 diabetes mellitus Diseases 0.000 claims description 16
• 108091008695 photoreceptors Proteins 0.000 claims description 15
• 229910052799 carbon Inorganic materials 0.000 claims description 14
• 230000005764 inhibitory process Effects 0.000 claims description 14
• 229910052757 nitrogen Inorganic materials 0.000 claims description 14
• 239000003795 chemical substances by application Substances 0.000 claims description 13
• 230000009918 complex formation Effects 0.000 claims description 12
• 230000002829 reductive effect Effects 0.000 claims description 11
• 230000000007 visual effect Effects 0.000 claims description 11
• 239000003963 antioxidant agent Substances 0.000 claims description 10
• 235000006708 antioxidants Nutrition 0.000 claims description 10
• 201000010934 exostosis Diseases 0.000 claims description 10
• 229910052739 hydrogen Inorganic materials 0.000 claims description 10
• 201000010930 hyperostosis Diseases 0.000 claims description 10
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
• 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 9
• WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 9
• 102000004190 Enzymes Human genes 0.000 claims description 9
• 108090000790 Enzymes Proteins 0.000 claims description 9
• 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 9
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
• 208000011580 syndromic disease Diseases 0.000 claims description 9
• 150000002367 halogens Chemical class 0.000 claims description 8
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 7
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 7
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 7
• 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 7
• 206010002022 amyloidosis Diseases 0.000 claims description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
• 208000024827 Alzheimer disease Diseases 0.000 claims description 6
• 239000005711 Benzoic acid Substances 0.000 claims description 6
• 235000010233 benzoic acid Nutrition 0.000 claims description 6
• 102000018832 Cytochromes Human genes 0.000 claims description 5
• 108010052832 Cytochromes Proteins 0.000 claims description 5
• 208000018127 Idiopathic intracranial hypertension Diseases 0.000 claims description 5
• 238000004519 manufacturing process Methods 0.000 claims description 5
• 208000001381 pseudotumor cerebri Diseases 0.000 claims description 5
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
• OPGXIVOGSNQWAY-UHFFFAOYSA-N 3-[(2-tert-butyl-4-chlorophenoxy)methyl]cyclopentane-1-carboxylic acid Chemical compound CC(C)(C)C1=CC(Cl)=CC=C1OCC1CC(C(O)=O)CC1 OPGXIVOGSNQWAY-UHFFFAOYSA-N 0.000 claims description 4
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
• 235000021466 carotenoid Nutrition 0.000 claims description 4
• 150000001747 carotenoids Chemical class 0.000 claims description 4
• 239000000539 dimer Substances 0.000 claims description 4
• 150000003904 phospholipids Chemical class 0.000 claims description 4
• NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 claims description 3
• GQZJXCWWWICSNA-UHFFFAOYSA-N 3-[(2-tert-butyl-4-chlorophenoxy)methyl]cyclohexane-1-carboxylic acid Chemical compound CC(C)(C)C1=CC(Cl)=CC=C1OCC1CC(C(O)=O)CCC1 GQZJXCWWWICSNA-UHFFFAOYSA-N 0.000 claims description 3
• SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 3
• QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 3
• 102100040756 Rhodopsin Human genes 0.000 claims description 3
• 108090000820 Rhodopsin Proteins 0.000 claims description 3
• 206010039729 Scotoma Diseases 0.000 claims description 3
• LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
• 230000003078 antioxidant effect Effects 0.000 claims description 3
• 235000021283 resveratrol Nutrition 0.000 claims description 3
• 229940016667 resveratrol Drugs 0.000 claims description 3
• HDUVFHYCOAXIEL-UHFFFAOYSA-N 3-[(2-tert-butyl-4-chloroanilino)methyl]cyclopentane-1-carboxamide Chemical compound CC(C)(C)C1=CC(Cl)=CC=C1NCC1CC(C(N)=O)CC1 HDUVFHYCOAXIEL-UHFFFAOYSA-N 0.000 claims description 2
• WLNCCKQPRPEHGG-UHFFFAOYSA-N 4-(2-tert-butyl-4-chlorophenoxy)butanoic acid Chemical compound CC(C)(C)C1=CC(Cl)=CC=C1OCCCC(O)=O WLNCCKQPRPEHGG-UHFFFAOYSA-N 0.000 claims description 2
• UVSNIHJFKAQJTI-UHFFFAOYSA-N 5-(2-tert-butyl-4-chlorophenoxy)-n-(4-hydroxyphenyl)pentanamide Chemical compound CC(C)(C)C1=CC(Cl)=CC=C1OCCCCC(=O)NC1=CC=C(O)C=C1 UVSNIHJFKAQJTI-UHFFFAOYSA-N 0.000 claims description 2
• KDUSFSMSZCTCFC-UHFFFAOYSA-N 5-(2-tert-butyl-4-chlorophenoxy)pentanoic acid Chemical compound CC(C)(C)C1=CC(Cl)=CC=C1OCCCCC(O)=O KDUSFSMSZCTCFC-UHFFFAOYSA-N 0.000 claims description 2
• WILYQPHCMRMJCA-UHFFFAOYSA-N 7-(2-tert-butyl-4-chlorophenoxy)heptanoic acid Chemical compound CC(C)(C)C1=CC(Cl)=CC=C1OCCCCCCC(O)=O WILYQPHCMRMJCA-UHFFFAOYSA-N 0.000 claims description 2
• 206010003694 Atrophy Diseases 0.000 claims description 2
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
• 208000001140 Night Blindness Diseases 0.000 claims description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
• 230000037444 atrophy Effects 0.000 claims description 2
• 239000000411 inducer Substances 0.000 claims description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
• 229960005280 isotretinoin Drugs 0.000 claims description 2
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims description 2
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims description 2
• 239000011707 mineral Substances 0.000 claims description 2
• 230000008929 regeneration Effects 0.000 claims description 2
• 238000011069 regeneration method Methods 0.000 claims description 2
• PJANXHGTPQOBST-VAWYXSNFSA-N trans-stilbene Chemical class C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 2
• 238000013518 transcription Methods 0.000 claims description 2
• 230000035897 transcription Effects 0.000 claims description 2
• 238000013519 translation Methods 0.000 claims description 2
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
• WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 claims 3
• 101000665882 Homo sapiens Retinol-binding protein 4 Proteins 0.000 claims 2
• 101150009274 nhr-1 gene Proteins 0.000 claims 2
• SKNPWISJZMCGMB-UHFFFAOYSA-N 4-[5-(2-tert-butyl-4-chlorophenoxy)pentanoylamino]benzamide Chemical compound CC(C)(C)C1=CC(Cl)=CC=C1OCCCCC(=O)NC1=CC=C(C(N)=O)C=C1 SKNPWISJZMCGMB-UHFFFAOYSA-N 0.000 claims 1
• LBECBVQTWIIETK-UHFFFAOYSA-N 5-(2-tert-butyl-4-chlorophenyl)sulfanylpentanoic acid Chemical compound CC(C)(C)C1=CC(Cl)=CC=C1SCCCCC(O)=O LBECBVQTWIIETK-UHFFFAOYSA-N 0.000 claims 1
• BURKQRZKFCTWJX-UHFFFAOYSA-N 7-(2-tert-butyl-4-chlorophenoxy)-n-(4-hydroxyphenyl)heptanamide Chemical compound CC(C)(C)C1=CC(Cl)=CC=C1OCCCCCCC(=O)NC1=CC=C(O)C=C1 BURKQRZKFCTWJX-UHFFFAOYSA-N 0.000 claims 1
• 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 1
• 230000003902 lesion Effects 0.000 claims 1
• 235000002639 sodium chloride Nutrition 0.000 description 65
• 101710137011 Retinol-binding protein 4 Proteins 0.000 description 44
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 33
• 235000019155 vitamin A Nutrition 0.000 description 33
• 239000011719 vitamin A Substances 0.000 description 33
• 229940045997 vitamin a Drugs 0.000 description 33
• 210000001519 tissue Anatomy 0.000 description 28
• 238000009472 formulation Methods 0.000 description 26
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
• 239000000243 solution Substances 0.000 description 25
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
• 238000007910 systemic administration Methods 0.000 description 24
• 241000699670 Mus sp. Species 0.000 description 23
• 238000012360 testing method Methods 0.000 description 23
• 239000000725 suspension Substances 0.000 description 21
• 230000015572 biosynthetic process Effects 0.000 description 20
• 210000004027 cell Anatomy 0.000 description 20
• 239000002552 dosage form Substances 0.000 description 20
• 239000004480 active ingredient Substances 0.000 description 19
• 229920001577 copolymer Polymers 0.000 description 18
• 239000000839 emulsion Substances 0.000 description 17
• 238000002347 injection Methods 0.000 description 17
• 239000007924 injection Substances 0.000 description 17
• 239000003981 vehicle Substances 0.000 description 17
• 238000005755 formation reaction Methods 0.000 description 16
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
• 230000004438 eyesight Effects 0.000 description 15
• 239000000126 substance Substances 0.000 description 15
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
• 239000003755 preservative agent Substances 0.000 description 14
• 230000009467 reduction Effects 0.000 description 14
• 229920002472 Starch Polymers 0.000 description 13
• 125000004429 atom Chemical group 0.000 description 13
• 210000004369 blood Anatomy 0.000 description 13
• 239000008280 blood Substances 0.000 description 13
• NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 13
• 235000019698 starch Nutrition 0.000 description 13
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
• 102000004877 Insulin Human genes 0.000 description 12
• 108090001061 Insulin Proteins 0.000 description 12
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 12
• 239000002775 capsule Substances 0.000 description 12
• 125000004432 carbon atom Chemical group C* 0.000 description 12
• 235000019441 ethanol Nutrition 0.000 description 12
• 239000000499 gel Substances 0.000 description 12
• 239000008273 gelatin Substances 0.000 description 12
• 229920000159 gelatin Polymers 0.000 description 12
• 229940014259 gelatin Drugs 0.000 description 12
• 229940125396 insulin Drugs 0.000 description 12
• 239000011159 matrix material Substances 0.000 description 12
• 229920001223 polyethylene glycol Polymers 0.000 description 12
• 229920000642 polymer Polymers 0.000 description 12
• 239000000843 powder Substances 0.000 description 12
• 235000018102 proteins Nutrition 0.000 description 12
• NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 12
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 11
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 11
• 108010010803 Gelatin Proteins 0.000 description 11
• 239000003085 diluting agent Substances 0.000 description 11
• 239000003814 drug Substances 0.000 description 11
• 235000019322 gelatine Nutrition 0.000 description 11
• 235000011852 gelatine desserts Nutrition 0.000 description 11
• 235000011187 glycerol Nutrition 0.000 description 11
• 229960005150 glycerol Drugs 0.000 description 11
• 230000012010 growth Effects 0.000 description 11
• 239000007788 liquid Substances 0.000 description 11
• 210000001525 retina Anatomy 0.000 description 11
• 239000002904 solvent Substances 0.000 description 11
• 235000010356 sorbitol Nutrition 0.000 description 11
• 239000003826 tablet Substances 0.000 description 11
• 201000003883 Cystic fibrosis Diseases 0.000 description 10
• 239000002253 acid Substances 0.000 description 10
• 229930002945 all-trans-retinaldehyde Natural products 0.000 description 10
• 238000004458 analytical method Methods 0.000 description 10
• 238000001514 detection method Methods 0.000 description 10
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 10
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 10
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 10
• 230000001965 increasing effect Effects 0.000 description 10
• 239000003921 oil Substances 0.000 description 10
• 210000000056 organ Anatomy 0.000 description 10
• 210000002381 plasma Anatomy 0.000 description 10
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 10
• 235000020945 retinal Nutrition 0.000 description 10
• 239000011604 retinal Substances 0.000 description 10
• 239000000600 sorbitol Substances 0.000 description 10
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
• 201000004569 Blindness Diseases 0.000 description 9
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 9
• 239000005977 Ethylene Substances 0.000 description 9
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
• 206010025421 Macule Diseases 0.000 description 9
• 239000002202 Polyethylene glycol Substances 0.000 description 9
• 208000027073 Stargardt disease Diseases 0.000 description 9
• 239000007891 compressed tablet Substances 0.000 description 9
• 238000013270 controlled release Methods 0.000 description 9
• 201000001727 diffuse idiopathic skeletal hyperostosis Diseases 0.000 description 9
• 229940079593 drug Drugs 0.000 description 9
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 9
• 239000008101 lactose Substances 0.000 description 9
• 230000035772 mutation Effects 0.000 description 9
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
• 230000002207 retinal effect Effects 0.000 description 9
• 239000011780 sodium chloride Substances 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 239000003381 stabilizer Substances 0.000 description 9
• 229920000858 Cyclodextrin Polymers 0.000 description 8
• 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 8
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 8
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 8
• 239000004372 Polyvinyl alcohol Substances 0.000 description 8
• 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 8
• 230000002159 abnormal effect Effects 0.000 description 8
• 239000012491 analyte Substances 0.000 description 8
• GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
• 208000035475 disorder Diseases 0.000 description 8
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 8
• 229940071826 hydroxyethyl cellulose Drugs 0.000 description 8
• 239000002502 liposome Substances 0.000 description 8
• 229920002451 polyvinyl alcohol Polymers 0.000 description 8
• 235000019422 polyvinyl alcohol Nutrition 0.000 description 8
• 239000011734 sodium Substances 0.000 description 8
• 239000008107 starch Substances 0.000 description 8
• 229940032147 starch Drugs 0.000 description 8
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
• 206010022489 Insulin Resistance Diseases 0.000 description 7
• 206010022773 Intracranial pressure increased Diseases 0.000 description 7
• 229930195725 Mannitol Natural products 0.000 description 7
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
• 239000007864 aqueous solution Substances 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• 230000004071 biological effect Effects 0.000 description 7
• 210000004204 blood vessel Anatomy 0.000 description 7
• 239000000969 carrier Substances 0.000 description 7
• 239000000460 chlorine Substances 0.000 description 7
• 230000007423 decrease Effects 0.000 description 7
• 239000002270 dispersing agent Substances 0.000 description 7
• 239000003995 emulsifying agent Substances 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 239000008103 glucose Substances 0.000 description 7
• 230000002209 hydrophobic effect Effects 0.000 description 7
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
• 201000009941 intracranial hypertension Diseases 0.000 description 7
• 239000008297 liquid dosage form Substances 0.000 description 7
• 239000000594 mannitol Substances 0.000 description 7
• 235000010355 mannitol Nutrition 0.000 description 7
• 235000019198 oils Nutrition 0.000 description 7
• 239000008203 oral pharmaceutical composition Substances 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 239000002243 precursor Substances 0.000 description 7
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
• 102000003849 Cytochrome P450 Human genes 0.000 description 6
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 239000004698 Polyethylene Substances 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
• 229930006000 Sucrose Natural products 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 239000011230 binding agent Substances 0.000 description 6
• 239000001768 carboxy methyl cellulose Substances 0.000 description 6
• 235000010980 cellulose Nutrition 0.000 description 6
• 229920002678 cellulose Polymers 0.000 description 6
• 239000006071 cream Substances 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 239000000796 flavoring agent Substances 0.000 description 6
• 239000008187 granular material Substances 0.000 description 6
• 210000003494 hepatocyte Anatomy 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• 230000003914 insulin secretion Effects 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 239000002674 ointment Substances 0.000 description 6
• 238000007911 parenteral administration Methods 0.000 description 6
• 229920000573 polyethylene Polymers 0.000 description 6
• 230000002335 preservative effect Effects 0.000 description 6
• 235000015424 sodium Nutrition 0.000 description 6
• 229910052708 sodium Inorganic materials 0.000 description 6
• SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 6
• 239000005720 sucrose Substances 0.000 description 6
• 239000000375 suspending agent Substances 0.000 description 6
• 229940117958 vinyl acetate Drugs 0.000 description 6
• 230000004393 visual impairment Effects 0.000 description 6
• 241000416162 Astragalus gummifer Species 0.000 description 5
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
• 241000894006 Bacteria Species 0.000 description 5
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
• 102000014914 Carrier Proteins Human genes 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
• 229920002125 Sokalan® Polymers 0.000 description 5
• 229920001615 Tragacanth Polymers 0.000 description 5
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
• XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 5
• 230000009102 absorption Effects 0.000 description 5
• 238000010521 absorption reaction Methods 0.000 description 5
• 150000007513 acids Chemical class 0.000 description 5
• 150000001413 amino acids Chemical group 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 229920002301 cellulose acetate Polymers 0.000 description 5
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
• 238000007906 compression Methods 0.000 description 5
• 239000006184 cosolvent Substances 0.000 description 5
• 239000007884 disintegrant Substances 0.000 description 5
• 239000003925 fat Substances 0.000 description 5
• 235000019197 fats Nutrition 0.000 description 5
• 239000012530 fluid Substances 0.000 description 5
• 235000003599 food sweetener Nutrition 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• 239000010410 layer Substances 0.000 description 5
• 239000000314 lubricant Substances 0.000 description 5
• 230000014759 maintenance of location Effects 0.000 description 5
• 229920000609 methyl cellulose Polymers 0.000 description 5
• 235000010981 methylcellulose Nutrition 0.000 description 5
• 239000001923 methylcellulose Substances 0.000 description 5
• 229960002900 methylcellulose Drugs 0.000 description 5
• 210000003097 mucus Anatomy 0.000 description 5
• 230000003204 osmotic effect Effects 0.000 description 5
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 5
• 229920000053 polysorbate 80 Polymers 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 239000000523 sample Substances 0.000 description 5
• 239000008299 semisolid dosage form Substances 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 239000003765 sweetening agent Substances 0.000 description 5
• 239000006188 syrup Substances 0.000 description 5
• 235000020357 syrup Nutrition 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 238000011200 topical administration Methods 0.000 description 5
• 239000000080 wetting agent Substances 0.000 description 5
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
• 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 4
• 239000001856 Ethyl cellulose Substances 0.000 description 4
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
• 208000035719 Maculopathy Diseases 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 208000008589 Obesity Diseases 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• 208000000208 Wet Macular Degeneration Diseases 0.000 description 4
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 4
• 239000000443 aerosol Substances 0.000 description 4
• 235000010443 alginic acid Nutrition 0.000 description 4
• 229920000615 alginic acid Polymers 0.000 description 4
• 235000001014 amino acid Nutrition 0.000 description 4
• 229940024606 amino acid Drugs 0.000 description 4
• 239000004599 antimicrobial Substances 0.000 description 4
• 239000008135 aqueous vehicle Substances 0.000 description 4
• 210000000988 bone and bone Anatomy 0.000 description 4
• 239000006172 buffering agent Substances 0.000 description 4
• 239000001913 cellulose Substances 0.000 description 4
• 239000002738 chelating agent Substances 0.000 description 4
• 230000004087 circulation Effects 0.000 description 4
• 239000003086 colorant Substances 0.000 description 4
• 230000006835 compression Effects 0.000 description 4
• 235000012343 cottonseed oil Nutrition 0.000 description 4
• 239000002385 cottonseed oil Substances 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 230000008021 deposition Effects 0.000 description 4
• 239000008121 dextrose Substances 0.000 description 4
• 235000014113 dietary fatty acids Nutrition 0.000 description 4
• 239000000975 dye Substances 0.000 description 4
• 235000019325 ethyl cellulose Nutrition 0.000 description 4
• 229920001249 ethyl cellulose Polymers 0.000 description 4
• LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
• 229930195729 fatty acid Natural products 0.000 description 4
• 239000000194 fatty acid Substances 0.000 description 4
• 239000000945 filler Substances 0.000 description 4
• 235000013355 food flavoring agent Nutrition 0.000 description 4
• 239000000017 hydrogel Substances 0.000 description 4
• 229920001477 hydrophilic polymer Polymers 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 239000007937 lozenge Substances 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 230000004060 metabolic process Effects 0.000 description 4
• 239000004005 microsphere Substances 0.000 description 4
• 235000020824 obesity Nutrition 0.000 description 4
• 229920000139 polyethylene terephthalate Polymers 0.000 description 4
• 239000005020 polyethylene terephthalate Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 239000006215 rectal suppository Substances 0.000 description 4
• CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
• 239000007921 spray Substances 0.000 description 4
• 239000004094 surface-active agent Substances 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 239000000454 talc Substances 0.000 description 4
• 229910052623 talc Inorganic materials 0.000 description 4
• 235000012222 talc Nutrition 0.000 description 4
• 231100000331 toxic Toxicity 0.000 description 4
• 230000002588 toxic effect Effects 0.000 description 4
• 235000010487 tragacanth Nutrition 0.000 description 4
• 229940116362 tragacanth Drugs 0.000 description 4
• 150000003626 triacylglycerols Chemical class 0.000 description 4
• 239000006216 vaginal suppository Substances 0.000 description 4
• AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 3
• 208000036443 AIPL1-related retinopathy Diseases 0.000 description 3
• YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
• 102000008186 Collagen Human genes 0.000 description 3
• 108010035532 Collagen Proteins 0.000 description 3
• 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 3
• 229920002307 Dextran Polymers 0.000 description 3
• 229920002907 Guar gum Polymers 0.000 description 3
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
• 229920000881 Modified starch Polymers 0.000 description 3
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
• CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
• 206010029113 Neovascularisation Diseases 0.000 description 3
• 201000007737 Retinal degeneration Diseases 0.000 description 3
• 229930003427 Vitamin E Natural products 0.000 description 3
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
• 210000000577 adipose tissue Anatomy 0.000 description 3
• 230000002776 aggregation Effects 0.000 description 3
• 238000004220 aggregation Methods 0.000 description 3
• 150000001336 alkenes Chemical class 0.000 description 3
• 150000001345 alkine derivatives Chemical group 0.000 description 3
• OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
• 150000001408 amides Chemical class 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 239000008346 aqueous phase Substances 0.000 description 3
• 235000010323 ascorbic acid Nutrition 0.000 description 3
• 239000011668 ascorbic acid Substances 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 235000013734 beta-carotene Nutrition 0.000 description 3
• 239000011648 beta-carotene Substances 0.000 description 3
• TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
• 229960002747 betacarotene Drugs 0.000 description 3
• 108091008324 binding proteins Proteins 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
• 229940105329 carboxymethylcellulose Drugs 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 229940106189 ceramide Drugs 0.000 description 3
• ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 229920001436 collagen Polymers 0.000 description 3
• 239000008139 complexing agent Substances 0.000 description 3
• 201000006754 cone-rod dystrophy Diseases 0.000 description 3
• 235000005687 corn oil Nutrition 0.000 description 3
• 239000002285 corn oil Substances 0.000 description 3
• 230000002596 correlated effect Effects 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 229960002086 dextran Drugs 0.000 description 3
• 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
• 239000002702 enteric coating Substances 0.000 description 3
• 238000009505 enteric coating Methods 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 229950003662 fenretinide Drugs 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
• 235000010417 guar gum Nutrition 0.000 description 3
• 239000000665 guar gum Substances 0.000 description 3
• 229960002154 guar gum Drugs 0.000 description 3
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
• 238000000265 homogenisation Methods 0.000 description 3
• 235000011167 hydrochloric acid Nutrition 0.000 description 3
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
• 229960000367 inositol Drugs 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 210000000936 intestine Anatomy 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 210000004153 islets of langerhan Anatomy 0.000 description 3
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
• 239000007951 isotonicity adjuster Substances 0.000 description 3
• 239000003589 local anesthetic agent Substances 0.000 description 3
• 229960005015 local anesthetics Drugs 0.000 description 3
• 208000018769 loss of vision Diseases 0.000 description 3
• 231100000864 loss of vision Toxicity 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 208000030159 metabolic disease Diseases 0.000 description 3
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
• 239000000693 micelle Substances 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
• VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
• 239000002687 nonaqueous vehicle Substances 0.000 description 3
• 239000002357 osmotic agent Substances 0.000 description 3
• 230000011164 ossification Effects 0.000 description 3
• 239000003002 pH adjusting agent Substances 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 235000019271 petrolatum Nutrition 0.000 description 3
• 239000008363 phosphate buffer Substances 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 235000011007 phosphoric acid Nutrition 0.000 description 3
• 210000000608 photoreceptor cell Anatomy 0.000 description 3
• 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
• 229940068886 polyethylene glycol 300 Drugs 0.000 description 3
• 229920001282 polysaccharide Polymers 0.000 description 3
• 239000005017 polysaccharide Substances 0.000 description 3
• 150000004804 polysaccharides Chemical class 0.000 description 3
• 229920002689 polyvinyl acetate Polymers 0.000 description 3
• 239000011118 polyvinyl acetate Substances 0.000 description 3
• 229920000915 polyvinyl chloride Polymers 0.000 description 3
• 239000004800 polyvinyl chloride Substances 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
• 230000004258 retinal degeneration Effects 0.000 description 3
• 150000004492 retinoid derivatives Chemical class 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 210000003786 sclera Anatomy 0.000 description 3
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 239000008159 sesame oil Substances 0.000 description 3
• 235000011803 sesame oil Nutrition 0.000 description 3
• 229920002379 silicone rubber Polymers 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
• 229940001584 sodium metabisulfite Drugs 0.000 description 3
• 235000010262 sodium metabisulphite Nutrition 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 229910052717 sulfur Inorganic materials 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 238000013268 sustained release Methods 0.000 description 3
• 239000012730 sustained-release form Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 239000002562 thickening agent Substances 0.000 description 3
• 230000032258 transport Effects 0.000 description 3
• 210000002700 urine Anatomy 0.000 description 3
• 229940088594 vitamin Drugs 0.000 description 3
• 229930003231 vitamin Natural products 0.000 description 3
• 235000013343 vitamin Nutrition 0.000 description 3
• 239000011782 vitamin Substances 0.000 description 3
• 235000019165 vitamin E Nutrition 0.000 description 3
• 239000011709 vitamin E Substances 0.000 description 3
• 229940046009 vitamin E Drugs 0.000 description 3
• 239000008136 water-miscible vehicle Substances 0.000 description 3
• 229920001285 xanthan gum Polymers 0.000 description 3
• 235000010493 xanthan gum Nutrition 0.000 description 3
• 239000000230 xanthan gum Substances 0.000 description 3
• 229940082509 xanthan gum Drugs 0.000 description 3
• 229910052725 zinc Inorganic materials 0.000 description 3
• 239000011701 zinc Substances 0.000 description 3
• OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
• DUUCJSJYISFGCI-WBPXWQEISA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-(dimethylamino)ethanol Chemical compound CN(C)CCO.OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O DUUCJSJYISFGCI-WBPXWQEISA-N 0.000 description 2
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
• OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 101710141544 Allatotropin-related peptide Proteins 0.000 description 2
• 239000005995 Aluminium silicate Substances 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
• 206010002023 Amyloidoses Diseases 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 208000034577 Benign intracranial hypertension Diseases 0.000 description 2
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
• SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
• 101150029409 CFTR gene Proteins 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 102000007768 Cellular Retinol-Binding Proteins Human genes 0.000 description 2
• 108010021988 Cellular Retinol-Binding Proteins Proteins 0.000 description 2
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
• DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 2
• 229920001661 Chitosan Polymers 0.000 description 2
• 108010062745 Chloride Channels Proteins 0.000 description 2
• 102000011045 Chloride Channels Human genes 0.000 description 2
• 239000004709 Chlorinated polyethylene Substances 0.000 description 2
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 241000792859 Enema Species 0.000 description 2
• IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
• 229920000896 Ethulose Polymers 0.000 description 2
• 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 2
• 229930091371 Fructose Natural products 0.000 description 2
• 239000005715 Fructose Substances 0.000 description 2
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
• 208000002705 Glucose Intolerance Diseases 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 244000043261 Hevea brasiliensis Species 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
• 108010044467 Isoenzymes Proteins 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
• CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
• 239000004677 Nylon Substances 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 235000019483 Peanut oil Nutrition 0.000 description 2
• 239000004264 Petrolatum Substances 0.000 description 2
• 239000005062 Polybutadiene Substances 0.000 description 2
• 229920002367 Polyisobutene Polymers 0.000 description 2
• 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 208000032430 Retinal dystrophy Diseases 0.000 description 2
• 239000008156 Ringer's lactate solution Substances 0.000 description 2
• 206010070834 Sensitisation Diseases 0.000 description 2
• 229920001800 Shellac Polymers 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 230000003187 abdominal effect Effects 0.000 description 2
• 150000001241 acetals Chemical class 0.000 description 2
• 235000011054 acetic acid Nutrition 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 239000000853 adhesive Substances 0.000 description 2
• 210000001789 adipocyte Anatomy 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 125000003545 alkoxy group Chemical group 0.000 description 2
• 235000019194 all-trans-retinaldehyde Nutrition 0.000 description 2
• 239000011751 all-trans-retinaldehyde Substances 0.000 description 2
• 239000011717 all-trans-retinol Substances 0.000 description 2
• 229940100609 all-trans-retinol Drugs 0.000 description 2
• 235000019169 all-trans-retinol Nutrition 0.000 description 2
• 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 235000012211 aluminium silicate Nutrition 0.000 description 2
• 150000001412 amines Chemical group 0.000 description 2
• 230000003941 amyloidogenesis Effects 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 230000001772 anti-angiogenic effect Effects 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 235000009697 arginine Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000000305 astragalus gummifer gum Substances 0.000 description 2
• 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 239000000440 bentonite Substances 0.000 description 2
• 229910000278 bentonite Inorganic materials 0.000 description 2
• 235000012216 bentonite Nutrition 0.000 description 2
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
• 229960000686 benzalkonium chloride Drugs 0.000 description 2
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 230000036760 body temperature Effects 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• 244000309464 bull Species 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 229920005549 butyl rubber Polymers 0.000 description 2
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
• 229960002681 calcium alginate Drugs 0.000 description 2
• 235000010410 calcium alginate Nutrition 0.000 description 2
• 239000000648 calcium alginate Substances 0.000 description 2
• 229910000019 calcium carbonate Inorganic materials 0.000 description 2
• 235000010216 calcium carbonate Nutrition 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 239000001569 carbon dioxide Substances 0.000 description 2
• 229910002092 carbon dioxide Inorganic materials 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 125000002843 carboxylic acid group Chemical group 0.000 description 2
• 235000010418 carrageenan Nutrition 0.000 description 2
• 229920001525 carrageenan Polymers 0.000 description 2
• 239000004359 castor oil Substances 0.000 description 2
• 235000019438 castor oil Nutrition 0.000 description 2
• 229920001727 cellulose butyrate Polymers 0.000 description 2
• 229920006218 cellulose propionate Polymers 0.000 description 2
• 229960000541 cetyl alcohol Drugs 0.000 description 2
• 239000007910 chewable tablet Substances 0.000 description 2
• 230000001055 chewing effect Effects 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 235000015165 citric acid Nutrition 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 229940125782 compound 2 Drugs 0.000 description 2
• 229940126214 compound 3 Drugs 0.000 description 2
• 229960000913 crospovidone Drugs 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 229940097362 cyclodextrins Drugs 0.000 description 2
• NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 230000006866 deterioration Effects 0.000 description 2
• 239000008355 dextrose injection Substances 0.000 description 2
• OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
• 239000007920 enema Substances 0.000 description 2
• 229940079360 enema for constipation Drugs 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 229920005558 epichlorohydrin rubber Polymers 0.000 description 2
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
• 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 2
• 235000010944 ethyl methyl cellulose Nutrition 0.000 description 2
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
• 229940093471 ethyl oleate Drugs 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 210000003608 fece Anatomy 0.000 description 2
• 239000010408 film Substances 0.000 description 2
• 239000007941 film coated tablet Substances 0.000 description 2
• 238000009501 film coating Methods 0.000 description 2
• 239000007888 film coating Substances 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 239000003349 gelling agent Substances 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
• 150000002334 glycols Chemical class 0.000 description 2
• 235000019314 gum ghatti Nutrition 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
• 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
• 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
• 201000008980 hyperinsulinism Diseases 0.000 description 2
• 201000006122 hypervitaminosis A Diseases 0.000 description 2
• 238000003119 immunoblot Methods 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 239000011261 inert gas Substances 0.000 description 2
• 210000002660 insulin-secreting cell Anatomy 0.000 description 2
• 238000007913 intrathecal administration Methods 0.000 description 2
• 238000007914 intraventricular administration Methods 0.000 description 2
• 239000003456 ion exchange resin Substances 0.000 description 2
• 229920003303 ion-exchange polymer Polymers 0.000 description 2
• 229920000554 ionomer Polymers 0.000 description 2
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
• 238000010902 jet-milling Methods 0.000 description 2
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 235000014655 lactic acid Nutrition 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
• 231100000053 low toxicity Toxicity 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 229920003087 methylethyl cellulose Polymers 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 239000002105 nanoparticle Substances 0.000 description 2
• 229920003052 natural elastomer Polymers 0.000 description 2
• 229920001194 natural rubber Polymers 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 239000002736 nonionic surfactant Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 229920001778 nylon Polymers 0.000 description 2
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 239000000312 peanut oil Substances 0.000 description 2
• 239000001814 pectin Substances 0.000 description 2
• 229920001277 pectin Polymers 0.000 description 2
• 235000010987 pectin Nutrition 0.000 description 2
• 229940066842 petrolatum Drugs 0.000 description 2
• 239000008177 pharmaceutical agent Substances 0.000 description 2
• ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 239000002504 physiological saline solution Substances 0.000 description 2
• 239000000049 pigment Substances 0.000 description 2
• 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 2
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
• 239000004584 polyacrylic acid Substances 0.000 description 2
• 229920002857 polybutadiene Polymers 0.000 description 2
• 125000003367 polycyclic group Chemical group 0.000 description 2
• 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
• 229920001195 polyisoprene Polymers 0.000 description 2
• 239000004926 polymethyl methacrylate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 229920001451 polypropylene glycol Polymers 0.000 description 2
• 229920001296 polysiloxane Polymers 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 229940068968 polysorbate 80 Drugs 0.000 description 2
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
• 239000001103 potassium chloride Substances 0.000 description 2
• 235000011164 potassium chloride Nutrition 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
• 229940081974 saccharin Drugs 0.000 description 2
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
• 235000019204 saccharin Nutrition 0.000 description 2
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 210000003296 saliva Anatomy 0.000 description 2
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
• 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 230000008313 sensitization Effects 0.000 description 2
• 239000003352 sequestering agent Substances 0.000 description 2
• 230000009528 severe injury Effects 0.000 description 2
• 229940113147 shellac Drugs 0.000 description 2
• 239000004208 shellac Substances 0.000 description 2
• 235000013874 shellac Nutrition 0.000 description 2
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• 229940005550 sodium alginate Drugs 0.000 description 2
• 235000010413 sodium alginate Nutrition 0.000 description 2
• 239000000661 sodium alginate Substances 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 description 2
• 235000017550 sodium carbonate Nutrition 0.000 description 2
• 235000011121 sodium hydroxide Nutrition 0.000 description 2
• 229920003109 sodium starch glycolate Polymers 0.000 description 2
• 239000008109 sodium starch glycolate Substances 0.000 description 2
• 229940079832 sodium starch glycolate Drugs 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 239000007901 soft capsule Substances 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 239000008137 solubility enhancer Substances 0.000 description 2
• 235000010199 sorbic acid Nutrition 0.000 description 2
• 239000004334 sorbic acid Substances 0.000 description 2
• 229940075582 sorbic acid Drugs 0.000 description 2
• 235000012424 soybean oil Nutrition 0.000 description 2
• 239000003549 soybean oil Substances 0.000 description 2
• 239000008117 stearic acid Substances 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 239000007940 sugar coated tablet Substances 0.000 description 2
• 238000009495 sugar coating Methods 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 210000004243 sweat Anatomy 0.000 description 2
• 210000001138 tear Anatomy 0.000 description 2
• 229920001897 terpolymer Polymers 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
• 125000003396 thiol group Chemical class [H]S* 0.000 description 2
• 229940034208 thyroxine Drugs 0.000 description 2
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
• 229930003799 tocopherol Natural products 0.000 description 2
• 235000010384 tocopherol Nutrition 0.000 description 2
• 229960001295 tocopherol Drugs 0.000 description 2
• 239000011732 tocopherol Substances 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 239000012049 topical pharmaceutical composition Substances 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 230000037317 transdermal delivery Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 230000009278 visceral effect Effects 0.000 description 2
• 150000003722 vitamin derivatives Chemical class 0.000 description 2
• 239000001993 wax Substances 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 238000009736 wetting Methods 0.000 description 2
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• GYYDPBCUIJTIBM-DYOGSRDZSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-[[(4r,5s)-4-hydroxy-3-methyl-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-methoxyoxane-3,5-diol Chemical compound O[C@@H]1[C@@H](OC)[C@@H](O)[C@@H](CO)OC1OC1[C@H]2OCC1OC(C)[C@H]2O GYYDPBCUIJTIBM-DYOGSRDZSA-N 0.000 description 1
• XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
• YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
• LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
• OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
• WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 1
• SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
• JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
• FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
• FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
• COBGWVGXUVRBBY-UHFFFAOYSA-N 2-[3-[(2-tert-butyl-4-chlorophenoxy)methyl]cyclopentyl]acetic acid Chemical compound CC(C)(C)C1=CC(Cl)=CC=C1OCC1CC(CC(O)=O)CC1 COBGWVGXUVRBBY-UHFFFAOYSA-N 0.000 description 1
• CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
• WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
• UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical class C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 1
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
• NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
• ZKKJLUXXPYMLBL-UHFFFAOYSA-N 4-[[3-[(2-tert-butyl-4-chlorophenoxy)methyl]cyclopentanecarbonyl]amino]benzoic acid Chemical compound CC(C)(C)C1=CC(Cl)=CC=C1OCC1CC(C(=O)NC=2C=CC(=CC=2)C(O)=O)CC1 ZKKJLUXXPYMLBL-UHFFFAOYSA-N 0.000 description 1
• PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 229910002012 Aerosil® Inorganic materials 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000001049 Amyloid Human genes 0.000 description 1
• 108010094108 Amyloid Proteins 0.000 description 1
• 244000106483 Anogeissus latifolia Species 0.000 description 1
• 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 208000010392 Bone Fractures Diseases 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 101100538857 Caenorhabditis elegans ttr-5 gene Proteins 0.000 description 1
• 208000004434 Calcinosis Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
• 108091006146 Channels Proteins 0.000 description 1
• 241001227713 Chiron Species 0.000 description 1
• 229920002101 Chitin Polymers 0.000 description 1
• 239000004155 Chlorine dioxide Substances 0.000 description 1
• 241000206575 Chondrus crispus Species 0.000 description 1
• 241000207199 Citrus Species 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
• 102100032260 DNA-directed RNA polymerase II subunit RPB4 Human genes 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• 102000016680 Dioxygenases Human genes 0.000 description 1
• 108010028143 Dioxygenases Proteins 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
• 229920003134 Eudragit® polymer Polymers 0.000 description 1
• 101710163305 Fibril protein Proteins 0.000 description 1
• 206010017076 Fracture Diseases 0.000 description 1
• 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 description 1
• 102400000321 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
• 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
• 102000042092 Glucose transporter family Human genes 0.000 description 1
• 108091052347 Glucose transporter family Proteins 0.000 description 1
• 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
• 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 239000001922 Gum ghatti Substances 0.000 description 1
• 229920000569 Gum karaya Polymers 0.000 description 1
• 108010023302 HDL Cholesterol Proteins 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 229920001499 Heparinoid Polymers 0.000 description 1
• 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 101100161494 Homo sapiens ABCA4 gene Proteins 0.000 description 1
• 101001088177 Homo sapiens DNA-directed RNA polymerase II subunit RPB4 Proteins 0.000 description 1
• 101000831949 Homo sapiens Receptor for retinol uptake STRA6 Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
• 206010058359 Hypogonadism Diseases 0.000 description 1
• 238000012404 In vitro experiment Methods 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 108010001127 Insulin Receptor Proteins 0.000 description 1
• 102000003746 Insulin Receptor Human genes 0.000 description 1
• 208000007976 Ketosis Diseases 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• 239000004166 Lanolin Substances 0.000 description 1
• 241000218652 Larix Species 0.000 description 1
• 235000005590 Larix decidua Nutrition 0.000 description 1
• 229920000161 Locust bean gum Polymers 0.000 description 1
• UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
• 241000195947 Lycopodium Species 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 239000005913 Maltodextrin Substances 0.000 description 1
• 229920002774 Maltodextrin Polymers 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 208000024556 Mendelian disease Diseases 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 208000001145 Metabolic Syndrome Diseases 0.000 description 1
• CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
• 229920000715 Mucilage Polymers 0.000 description 1
• 208000023178 Musculoskeletal disease Diseases 0.000 description 1
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• 206010028741 Nasal inflammation Diseases 0.000 description 1
• 206010028748 Nasal obstruction Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 102000010175 Opsin Human genes 0.000 description 1
• 108050001704 Opsin Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 235000021314 Palmitic acid Nutrition 0.000 description 1
• 201000010183 Papilledema Diseases 0.000 description 1
• 206010033712 Papilloedema Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 206010034960 Photophobia Diseases 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
• 229920000148 Polycarbophil calcium Polymers 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
• HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
• 208000002607 Pseudarthrosis Diseases 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 239000004373 Pullulan Substances 0.000 description 1
• 229920001218 Pullulan Polymers 0.000 description 1
• MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
• 102100024235 Receptor for retinol uptake STRA6 Human genes 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 108091006300 SLC2A4 Proteins 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 229920002305 Schizophyllan Polymers 0.000 description 1
• 208000032023 Signs and Symptoms Diseases 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 239000004147 Sorbitan trioleate Substances 0.000 description 1
• PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
• 235000019486 Sunflower oil Nutrition 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 240000006474 Theobroma bicolor Species 0.000 description 1
• 239000003490 Thiodipropionic acid Substances 0.000 description 1
• 208000009205 Tinnitus Diseases 0.000 description 1
• 108060008539 Transglutaminase Proteins 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
• XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 108010059993 Vancomycin Proteins 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 206010047513 Vision blurred Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000000862 absorption spectrum Methods 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 201000010272 acanthosis nigricans Diseases 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
• VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
• ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
• UGZICOVULPINFH-UHFFFAOYSA-N acetic acid;butanoic acid Chemical compound CC(O)=O.CCCC(O)=O UGZICOVULPINFH-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 239000002280 amphoteric surfactant Substances 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 229940031955 anhydrous lanolin Drugs 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 239000003945 anionic surfactant Substances 0.000 description 1
• 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001896 anti-amyloidogenic effect Effects 0.000 description 1
• 230000003527 anti-angiogenesis Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 239000008122 artificial sweetener Substances 0.000 description 1
• 235000021311 artificial sweeteners Nutrition 0.000 description 1
• 125000005110 aryl thio group Chemical group 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• 239000012911 assay medium Substances 0.000 description 1
• 210000003403 autonomic nervous system Anatomy 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
• 229960001950 benzethonium chloride Drugs 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
• 229960004853 betadex Drugs 0.000 description 1
• 239000000227 bioadhesive Substances 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000008468 bone growth Effects 0.000 description 1
• 229910021538 borax Inorganic materials 0.000 description 1
• 235000010338 boric acid Nutrition 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• 230000002308 calcification Effects 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical compound [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
• 239000004203 carnauba wax Substances 0.000 description 1
• 235000013869 carnauba wax Nutrition 0.000 description 1
• 150000001746 carotenes Chemical class 0.000 description 1
• 235000005473 carotenes Nutrition 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 230000001925 catabolic effect Effects 0.000 description 1
• 239000003729 cation exchange resin Substances 0.000 description 1
• 229940023913 cation exchange resins Drugs 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 239000003093 cationic surfactant Substances 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
• WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 1
• 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
• NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 235000019398 chlorine dioxide Nutrition 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• BWRHOYDPVJPXMF-UHFFFAOYSA-N cis-Caran Natural products C1C(C)CCC2C(C)(C)C12 BWRHOYDPVJPXMF-UHFFFAOYSA-N 0.000 description 1
• 229960004106 citric acid Drugs 0.000 description 1
• 235000020971 citrus fruits Nutrition 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 230000004456 color vision Effects 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000000536 complexating effect Effects 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 238000003271 compound fluorescence assay Methods 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000003433 contraceptive agent Substances 0.000 description 1
• 229940124558 contraceptive agent Drugs 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 206010011005 corneal dystrophy Diseases 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• 150000001896 cresols Chemical class 0.000 description 1
• 229960005168 croscarmellose Drugs 0.000 description 1
• 229920006037 cross link polymer Polymers 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
• 239000002577 cryoprotective agent Substances 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 1
• 230000004300 dark adaptation Effects 0.000 description 1
• 231100000895 deafness Toxicity 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000000326 densiometry Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 229940096516 dextrates Drugs 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• 235000015872 dietary supplement Nutrition 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 238000007907 direct compression Methods 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000012990 dithiocarbamate Substances 0.000 description 1
• 150000004659 dithiocarbamates Chemical class 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000007908 dry granulation Methods 0.000 description 1
• 238000010410 dusting Methods 0.000 description 1
• 208000033530 early-onset macular degeneration Diseases 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 239000007911 effervescent powder Substances 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 239000002662 enteric coated tablet Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
• SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000003777 experimental drug Substances 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
• 238000002189 fluorescence spectrum Methods 0.000 description 1
• 229960002714 fluticasone Drugs 0.000 description 1
• MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000001408 fungistatic effect Effects 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• 230000024924 glomerular filtration Effects 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
• 210000002288 golgi apparatus Anatomy 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 239000002554 heparinoid Substances 0.000 description 1
• 229940025770 heparinoids Drugs 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 239000010903 husk Substances 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
• 239000008173 hydrogenated soybean oil Substances 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 239000008311 hydrophilic ointment Substances 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 229960004337 hydroquinone Drugs 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
• 230000003345 hyperglycaemic effect Effects 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
• 239000007946 hypodermic tablet Substances 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000007915 intraurethral administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 230000002262 irrigation Effects 0.000 description 1
• 238000003973 irrigation Methods 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 238000006317 isomerization reaction Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 235000010494 karaya gum Nutrition 0.000 description 1
• 230000004140 ketosis Effects 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 229940039717 lanolin Drugs 0.000 description 1
• 235000019388 lanolin Nutrition 0.000 description 1
• 239000007942 layered tablet Substances 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 229960004873 levomenthol Drugs 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• 229940059904 light mineral oil Drugs 0.000 description 1
• 208000013469 light sensitivity Diseases 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 235000010420 locust bean gum Nutrition 0.000 description 1
• 239000000711 locust bean gum Substances 0.000 description 1
• 210000004446 longitudinal ligament Anatomy 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 231100000516 lung damage Toxicity 0.000 description 1
• 230000004199 lung function Effects 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 230000031852 maintenance of location in cell Effects 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229940035034 maltodextrin Drugs 0.000 description 1
• 235000012054 meals Nutrition 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 229940057917 medium chain triglycerides Drugs 0.000 description 1
• 238000007909 melt granulation Methods 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
• 229940041616 menthol Drugs 0.000 description 1
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
• 229910052753 mercury Inorganic materials 0.000 description 1
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 239000004200 microcrystalline wax Substances 0.000 description 1
• 235000019808 microcrystalline wax Nutrition 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000003595 mist Substances 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 235000013379 molasses Nutrition 0.000 description 1
• 238000012806 monitoring device Methods 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
• 238000000465 moulding Methods 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
• 239000002077 nanosphere Substances 0.000 description 1
• 239000007923 nasal drop Substances 0.000 description 1
• 229940100662 nasal drops Drugs 0.000 description 1
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 235000019645 odor Nutrition 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 230000004768 organ dysfunction Effects 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 229920000620 organic polymer Polymers 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• 239000003346 palm kernel oil Substances 0.000 description 1
• 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 229960000292 pectin Drugs 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• HUPQYPMULVBQDL-UHFFFAOYSA-N pentanoic acid Chemical compound CCCCC(O)=O.CCCCC(O)=O HUPQYPMULVBQDL-UHFFFAOYSA-N 0.000 description 1
• 229940043138 pentosan polysulfate Drugs 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
• 235000019477 peppermint oil Nutrition 0.000 description 1
• 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 150000002989 phenols Chemical class 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 229960000969 phenyl salicylate Drugs 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 229960000540 polacrilin potassium Drugs 0.000 description 1
• 229920001308 poly(aminoacid) Polymers 0.000 description 1
• 229920001084 poly(chloroprene) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 229950005134 polycarbophil Drugs 0.000 description 1
• 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
• 229920000151 polyglycol Polymers 0.000 description 1
• 239000010695 polyglycol Substances 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
• 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229940068977 polysorbate 20 Drugs 0.000 description 1
• 229920002635 polyurethane Polymers 0.000 description 1
• 239000004814 polyurethane Substances 0.000 description 1
• 231100000683 possible toxicity Toxicity 0.000 description 1
• 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
• 229910052939 potassium sulfate Inorganic materials 0.000 description 1
• 235000011151 potassium sulphates Nutrition 0.000 description 1
• WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 229920003124 powdered cellulose Polymers 0.000 description 1
• 235000019814 powdered cellulose Nutrition 0.000 description 1
• 201000009104 prediabetes syndrome Diseases 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 208000022256 primary systemic amyloidosis Diseases 0.000 description 1
• 229960001309 procaine hydrochloride Drugs 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
• 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 235000010388 propyl gallate Nutrition 0.000 description 1
• 229940075579 propyl gallate Drugs 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
• 229940093625 propylene glycol monostearate Drugs 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000029983 protein stabilization Effects 0.000 description 1
• 235000019423 pullulan Nutrition 0.000 description 1
• 230000000541 pulsatile effect Effects 0.000 description 1
• 235000021251 pulses Nutrition 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
• 230000009103 reabsorption Effects 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 229940096976 rectal foam Drugs 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000026304 regulation of glucose transport Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000013878 renal filtration Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000033458 reproduction Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 125000002523 retinol group Chemical group 0.000 description 1
• 201000007714 retinoschisis Diseases 0.000 description 1
• WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 229940085605 saccharin sodium Drugs 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 235000019613 sensory perceptions of taste Nutrition 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 229960003885 sodium benzoate Drugs 0.000 description 1
• 239000008354 sodium chloride injection Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 235000011083 sodium citrates Nutrition 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 239000001540 sodium lactate Substances 0.000 description 1
• 235000011088 sodium lactate Nutrition 0.000 description 1
• 229940005581 sodium lactate Drugs 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 235000011008 sodium phosphates Nutrition 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 235000010339 sodium tetraborate Nutrition 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 239000002195 soluble material Substances 0.000 description 1
• 229940035049 sorbitan monooleate Drugs 0.000 description 1
• 235000011069 sorbitan monooleate Nutrition 0.000 description 1
• 239000001593 sorbitan monooleate Substances 0.000 description 1
• 235000019337 sorbitan trioleate Nutrition 0.000 description 1
• 229960000391 sorbitan trioleate Drugs 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 239000012177 spermaceti Substances 0.000 description 1
• 229940084106 spermaceti Drugs 0.000 description 1
• 238000001694 spray drying Methods 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 210000004500 stellate cell Anatomy 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 239000003351 stiffener Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 210000000352 storage cell Anatomy 0.000 description 1
• 238000005728 strengthening Methods 0.000 description 1
• 210000004003 subcutaneous fat Anatomy 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 239000002600 sunflower oil Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000001360 synchronised effect Effects 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 230000035488 systolic blood pressure Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 235000019640 taste Nutrition 0.000 description 1
• 230000035923 taste sensation Effects 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
• ZUHZGEOKBKGPSW-UHFFFAOYSA-N tetraglyme Chemical compound COCCOCCOCCOCCOC ZUHZGEOKBKGPSW-UHFFFAOYSA-N 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
• 235000019303 thiodipropionic acid Nutrition 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 229960004906 thiomersal Drugs 0.000 description 1
• DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
• 230000009974 thixotropic effect Effects 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 231100000886 tinnitus Toxicity 0.000 description 1
• NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
• 229960000707 tobramycin Drugs 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 102000003601 transglutaminase Human genes 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• 229940117013 triethanolamine oleate Drugs 0.000 description 1
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
• YFNKIDBQEZZDLK-UHFFFAOYSA-N triglyme Chemical compound COCCOCCOCCOC YFNKIDBQEZZDLK-UHFFFAOYSA-N 0.000 description 1
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• 229960004418 trolamine Drugs 0.000 description 1
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
• 229920011532 unplasticized polyvinyl chloride Polymers 0.000 description 1
• 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
• 239000006217 urethral suppository Substances 0.000 description 1
• 230000036325 urinary excretion Effects 0.000 description 1
• 229940120293 vaginal suppository Drugs 0.000 description 1
• MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
• 229960003165 vancomycin Drugs 0.000 description 1
• MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 235000020797 vitamin A status Nutrition 0.000 description 1
• 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
• 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 238000005550 wet granulation Methods 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1
• 208000027121 wild type ATTR amyloidosis Diseases 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1
• XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1